Vitamin B12 shows no heart attack benefitUrinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial.
In a recent study, we delved into the role of homocysteine thiolactone, a metabolite linked to heart disease, in predicting the risk of acute myocardial infarction (AMI). Conducted with a sizable group of 2049 patients suspected of having coronary artery disease (CAD), the trial was meticulously designed as a double-blind clinical intervention.
Participants were divided randomly into four distinct groups, receiving a combination of folic acid and other B vitamins or a placebo. Notably, we measured urinary levels of homocysteine thiolactone at different points throughout the study to draw correlations with heart attack incidents.
Our analysis revealed that while the homocysteine thiolactone/creatinine ratio was a significant predictor of AMI risk, there was no observable effect from the vitamin B treatments received by participants. This suggests that vitamin B12, when part of a group of B vitamins, did not independently influence the likelihood of having a heart attack.
Ultimately, we found that higher levels of homocysteine thiolactone correlated with a greater risk of AMI, but the combination of vitamin B treatments did not alter this outcome. This points to the potential of homocysteine thiolactone as an important marker in understanding cardiovascular health.
Joint pain relief
Most Useful Review
Good. I had never tried this brand before, but I’m pleased I did. It alleviated my joint pain and muscle aches. The pills have no taste, and they are tiny, but the ingredients are of high quality. The packaging is excellent, and it provides minerals, hormones, omega, and benefits for inflammation, cholesterol, heart health, and hair.